← Back to Screener
Cellectar Biosciences INC NEW (CLRB)
Price$3.01
Favorite Metrics
Price vs S&P 500 (26W)-40.39%
Price vs S&P 500 (4W)-12.28%
Market Capitalization$13.06M
All Metrics
Book Value / Share (Quarterly)$2.34
P/TBV (Annual)1.66x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.45
Price vs S&P 500 (YTD)0.41%
Net Profit Margin (TTM)-24744.44%
EPS (TTM)$-10.38
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-10.38
EPS (Annual)$-8.35
ROI (Annual)-219.69%
Cash / Share (Quarterly)$3.11
ROA (Last FY)-145.48%
EBITD / Share (TTM)$-8.74
ROE (5Y Avg)-157.80%
Operating Margin (TTM)-11300.00%
Cash Flow / Share (Annual)$-5.45
P/B Ratio1.32x
P/B Ratio (Quarterly)1.26x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)-1.52x
Net Interest Coverage (TTM)-10.07x
ROA (TTM)-146.88%
EPS Incl Extra (Annual)$-8.35
Current Ratio (Annual)2.96x
Quick Ratio (Quarterly)2.78x
3-Month Avg Trading Volume0.06M
52-Week Price Return-65.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.46
P/S Ratio (Annual)130.60x
Asset Turnover (Annual)0.01x
52-Week High$20.70
EPS Excl Extra (Annual)$-8.35
CapEx CAGR (5Y)-37.16%
Tangible BV CAGR (5Y)11.30%
26-Week Price Return-36.40%
Quick Ratio (Annual)2.78x
13-Week Price Return-20.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.96x
Enterprise Value$-0.136
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-24.66%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-22270.00%
Cash / Share (Annual)$3.11
3-Month Return Std Dev86.48%
Net Income / Employee (TTM)$-2
ROE (Last FY)-219.69%
Net Interest Coverage (Annual)-13.03x
EPS Basic Excl Extra (Annual)$-8.35
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-10.38
ROI (TTM)-239.46%
P/S Ratio (TTM)145.11x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.65
Price vs S&P 500 (52W)-94.89%
Year-to-Date Return3.05%
5-Day Price Return7.80%
EPS Normalized (Annual)$-8.35
ROA (5Y Avg)-174.40%
Net Profit Margin (Annual)-22270.00%
Month-to-Date Return19.68%
Cash Flow / Share (TTM)$-3.44
EBITD / Share (Annual)$-8.73
Operating Margin (Annual)-10170.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-157.80%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-10.38
P/TBV (Quarterly)5.65x
P/B Ratio (Annual)1.26x
Pretax Margin (TTM)-24744.44%
Book Value / Share (Annual)$2.34
Price vs S&P 500 (13W)-20.69%
Beta0.53x
Revenue / Share (TTM)$0.00
ROE (TTM)-239.46%
52-Week Low$2.43
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CLRBCellectar Biosciences INC NEW | 145.11x | — | — | — | $3.01 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Cellectar Biosciences is a clinical-stage biopharmaceutical company developing cancer therapeutics using its proprietary phospholipid drug conjugate (PDC) delivery platform. The company's PDC technology is designed to selectively target cancer cells, potentially offering improved efficacy with reduced off-target toxicity compared to conventional approaches. Cellectar is leveraging this platform to build a pipeline of oncology drugs aimed at addressing unmet patient needs in cancer treatment.